Use various methods to manage the nonmotor adverse effects of dopamine receptor agonists in Parkinson's disease

Author：

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.26, Iss.12, 2010-12, pp. : 23-26

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Review and Treatment of Select Adverse Effects of Dopamine Receptor Agonists in Parkinson's Disease

By Wood Lindy D.

Drugs & Aging, Vol. 27, Iss. 4, 2010-04 ,pp. : 295-310

Adis International

Access to resources Recommend Favorite

Are Dopamine Receptor Agonists Neuroprotective in Parkinson's Disease?

By Le W-D. Jankovic J.

Drugs & Aging, Vol. 18, Iss. 6, 2001-06 ,pp. : 389-396

Adis International

Access to resources Recommend Favorite

Dopamine agonists in Parkinson’s disease

By Tintner Ron Jankovic Joseph

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 11, 2003-11 ,pp. : 1803-1820

Informa Healthcare

Access to resources Recommend Favorite

Effects of -opioid receptor agonists on long-term cocaine use and dopamine neurotransmission

By Collins S.L. D'Addario C. Izenwasser S.

European Journal of Pharmacology, Vol. 426, Iss. 1, 2001-08 ,pp. : 25-34

Elsevier

Access to resources Recommend Favorite

Clinical Pharmacology of Dopamine Agonists in Parkinson's Disease

By Lange K.W.

Drugs & Aging, Vol. 13, Iss. 5, 1998-11 ,pp. : 381-389

Adis International

Access to resources Recommend Favorite